Trial · NCT04735432
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change From Baseline in Total IgG Levels at Day 29 (mITT Analysis Set) | From week 0 to week 4 | percent | LEAST_SQUARES_MEAN | |
| SECONDARY | Percent Change From Baseline in Total IgG Levels Over Time (mITT Analysis Set) | From baseline to week 10 | mITT Analysis Set: All randomized participants with a value for total IgG levels at baseline and at least 1 postbaseline timepoint. | percent | MEAN |
| SECONDARY | Percent Change From Baseline in AChR-Ab Levels Over Time in AChR- Ab Positive Patients (mITT Analysis Set) | From baseline to week 10 | percent | MEAN | |
| SECONDARY | Percent Change From Baseline in IgG Subtype Levels Over Time (mITT Analysis Set) | Baseline to week 10 | mITT Analysis Set: All randomized participants with a value for total IgG levels at baseline and at least 1 postbaseline timepoint. | Percent change | MEDIAN |
| SECONDARY | AUEC of the Percent Change From Baseline in Total IgG Level (mITT Analysis Set) | From baseline to week 10 | percent days | MEAN | |
| SECONDARY | Еfgartigimod IV and PH20 SC Serum Pharmacokinetic Parameter Ctrough | From Week 1 to Week 4. | μg/mL | MEAN | |
| SECONDARY | Efgartigimod IV Serum Pharmacokinetic Parameter Cmax | From Baseline to Week 3 | μg/mL | MEAN | |
| SECONDARY | Incidence of ADA Against Efgartigimod (Safety Analysis Set) | From baseline to week 10 | Percent of patients | NUMBER | |
| SECONDARY | Incidence of Antibodies Against rHuPH20 in the SC Treatment Arm (Safety Analysis Set) | From baseline to week 10 | Percent of patients | NUMBER | |
| SECONDARY | Incidence and Severity of AEs and SAEs (Safety Analysis Set) | From baseline to week 10 | Percent of patients | NUMBER | |
| SECONDARY | MG-ADL Responders (ITT Analysis Set) | From baseline to week 10 | percent | NUMBER | |
| SECONDARY | QMG Responders (ITT Analysis Set) | From Baseline to Week 10 | One patient from Efgartigimod IV didn't have any post-baseline QMG assessment. | percent | NUMBER |
| SECONDARY | Change From Baseline in MG-ADL Total Score Over Time (ITT Analysis Set) | From baseline to week 10 | Total score on a scale | MEAN | |
| SECONDARY | Change From Baseline in QMG Score Over Time (ITT Analysis Set) | From baseline to week 10 | Total score | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04735432/outcomes